Strategies for Vaccine Delivery

References

• Almeida, A.J. and Alpar, H.O. (1996) “Nasal delivery of vaccines”, J. Drug Target. 3, 455–467.
   PubMed Web of Science ®Google Scholar
• Alpar, H.O. and Almeida, A.J. (1994) “Identification of some of the physico-chemical characteristics of microspheres which influence the induction of thr immune response following mucosal delivery”, Eur. J. Pharm. Biopharm. 40, 198–202.
   Google Scholar
• Alpar, H.O. and Bramwell, V.W. (2002) “Current status of DNA vaccines and their route of administration”, Crit. Rev. Ther. Drug Carrier Syst. 19, 307–383.
   PubMed Web of Science ®Google Scholar
• Alpar, H.O., Bowen, J.C. and Brown, M.R.W. (1992) “Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid”, Int. J. Pharm. 88, 335–344.
   Google Scholar
• Alpar, H.O., Almeida, A.J. and Brown, M.R. (1994) “Microsphere absorption by the nasal mucosa of the rat”, J. Drug Target. 2, 147–149. Alpar, H.O., Ozsoy, Y., Bowen, J.C., Eyles, J., Conway, B.R. and Williamson, D.E. (1996) “Potential of particulate carriers for the mucosal delivery of DNA vaccines”, Immunology 89, CC337-CC337.
   Google Scholar
• Alpar, H.O., Eyles, J.E., Williamson, E.D. and Somavarapu, S. (2001) “Intranasal vaccination against plague, tetanus and diphtheria”, Adv. Drug Deliv. Rev. 51, 173–201.
   PubMed Web of Science ®Google Scholar
• Capiau, C., Poolman, J., Hoet, B., Bogaerts, H. and Andre, F. (2003) “Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encoun- tered and lessons learned”, Vaccine 21, 2273–2287.
   PubMed Web of Science ®Google Scholar
• Degen, W.G., Jansen, T. and Schijns, V.E. (2003) “Vaccine adjuvant technology: from mechanistic concepts to practical applications”, Expert Rev. Vaccines 2, 327–335.
   Google Scholar
• Eyles, J., Alpar, O., Field, W.N., Lewis, D.A. and Keswick, M. (1995) “The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat”, J. Pharm. Pharmacol. 47, 561–565.
   PubMed Web of Science ®Google Scholar
• Eyles, J.E., Alpar, H.O., Conway, B.R. and Keswick, M. (1997) “Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats”, J. Pharm. Pharmacol. 49, 669–674.
   PubMed Web of Science ®Google Scholar
• Eyles, J.E., Sharp, G.J.E., Williamson, E.D., Spiers, I.D. and Alpar, H.O. (1998) “Intra nasal administration of poly-lactic acid microsphere co- encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse”, Vaccine 16, 698–707.
   PubMed Web of Science ®Google Scholar
• Eyles, J.E., Williamson, E.D. and Alpar, H.O. (2000) “Intranasal administration of influenza vaccines—current status”, Biodrugs 13, 35–59.
   PubMed Web of Science ®Google Scholar
• Eyles, J.E., Bramwell, V.W., Williamson, E.D. and Alpar, H.O. (2001) “Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration”, Vaccine 19, 4732–4742.
   PubMed Web of Science ®Google Scholar
• Fujihashi, K., Dohi, T., Rennert, P.D., Yamamoto, M., Koga, T., Kiyono, H. and McGhee, J.R. (2001) “Peyer’s patches are required for oral tolerance to proteins”, PNAS 98, 3310–3315.
   PubMed Web of Science ®Google Scholar
• Janeway, C.A., Jr. (1992) “The immune system evolved to discriminate infectious nonself from noninfectious self”, Immunol. Today 13, 11–16.
   Google Scholar
• Klinman, D.M., Barnhart, K.M. and Conover, J. (1999) “CpG motifs as immune adjuvants”, Vaccine 17, 19–25.
   PubMed Web of Science ®Google Scholar
• Lasic, D.D. and Templeton, N.S. (1996) “Liposomes in gene therapy”, Adv. Drug Deliv. Rev. 20, 221–266.
   Web of Science ®Google Scholar
• Le Saux, N., Barrowman, N.J., Moore, D.L., Whiting, S., Scheifele, D. and Halperin, S. (2003) “Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT”, Pediatrics 112, e348.
   Google Scholar
• Li, X.W., Lee, D.K., Chan, A.S. and Alpar, H.O. (2003) “Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles”, Biochim. Biophys. Acta 1630, 7–18.
   PubMed Web of Science ®Google Scholar
• Liu, M.A. (1999) “Vaccines timeline. Interview by Philip Cohen”, BMJ 319, 1301.
   PubMedGoogle Scholar
• van der Lubben, I.M., van Opdorp, F.A., Hengeveld, M.R., Onderwater, J.J., Koerten, H.K., Verhoef, J.C., Borchard, G. and Junginger, H.E. (2002) “Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model”, J. Drug Target. 10, 449–456.
   PubMed Web of Science ®Google Scholar
• McCluskie, M.J., Chu, Y., Xia, J.L., Jessee, J., Gebyehu, G. and Davis, H.L. (1998) “Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA”, Antisense Nucleic Acid Drug Dev. 8, 401–414.
   PubMedGoogle Scholar
• Ogra, P.L., Chiba, Y., Beutner, K.R. and Morag, A. (1976) “Vaccination by non-parenteral routes: characteristics of immune response”, Dev. Biol. Stand. 33, 19–26.
   PubMedGoogle Scholar
• Perrie, Y., Frederik, P.M. and Gregoriadis, G. (2001) “Liposome- mediated DNA vaccination: the effect of vesicle composition”, Vaccine 19, 3301–3310.
   PubMed Web of Science ®Google Scholar
• Schijns, V.E. (2003) “Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants”, Vaccine 21, 829–831.
   PubMed Web of Science ®Google Scholar
• Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S., Marincola, F.M., Leitner, W.W. and Restifo, N.P. (1999) “Cancer therapy using a self-replicating RNA vaccine”, Nat. Med. 5, 823–827.
   Web of Science ®Google Scholar